Retatrutide, from Soma Corp., is gaining increasing attention as a innovative treatment for metabolic control . This innovative compound merges the properties of a GLP-1 receptor activator and a GIP receptor agonist , designed to not only promote weight loss but also address related metabolic conditions . Early clinical trials have demonstrated pro